Incannex Healthcare stock tumbles after filing $100M offering
Investing.com - Berenberg initiated coverage on Innoscripta SE (1INN:GR) with a Buy rating and a price target of EUR200.00 on Tuesday.
The German company offers a complete software platform for businesses to claim R&D tax credits and manage their R&D projects, positioning it early in a nascent market.
Berenberg expects Innoscripta to benefit significantly from rising R&D tax credit adoption in Germany, projecting sales and EBIT compound annual growth rates of 33% and 28% respectively over the next five years.
The research firm noted that at 12.9x 2026 EV/EBIT, Innoscripta shares currently trade at a substantial discount compared to peers in the sector.
Berenberg suggested investors may have underestimated Innoscripta’s growth potential, with the firm believing the stock could potentially double from its current level.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.